Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion

Korobelnik, Jean‐François; Holz, Frank G.; Roider, Johann; Ogura, Yuichiro; Simader, Christian; Schmidt‐Erfurth, Ursula; Lorenz, Katrin; Honda, Miki; Vitti, Robert; Berliner, Alyson J.; Hiemeyer, Florian; Stemper, Brigitte; Zeitz, Oliver; Sandbrink, Rupert

doi:10.1016/j.ophtha.2013.08.012

Cited by 253 publications

(298 citation statements)

References 12 publications

Supporting

Mentioning

253

Contrasting

Unclassified

Order By: Relevance

“…These results were also mirrored by the GALILEO study that showed 18-letter improvements by 24 weeks that dropped to 16.9 letters at the end of the first year and 13.7 letters at 76 weeks. 18 In addition, 80% of patients had no fluid on OCT at week 24 compared with 60.2% at 76 weeks. This deterioration in visual acuity in both studies can be explained by the extended duration of follow-ups in studies.…”

Section: Afliberceptmentioning

confidence: 98%

See 1 more Smart Citation

Central retinal vein occlusion: modifying current treatment protocols

Ashraf

Souka

Singh

2016

Eye

View full text Add to dashboard Cite

Central retinal vein occlusion (CRVO) is a common retinal vascular disorder that can result in severe visual acuity loss. The randomized control study, CRUISE, helped establish anti-VEGFs as the standard of care in cases with CRVO. The extension studies for CRUISE; HORIZON and RETAIN showed that not all visual gains are maintained beyond the first year. In addition, patients showed different behavior patterns; with some patients showing complete response with few recurrences, whereas others showed partial or even no response with multiple recurrences. Long-term follow-up demonstrated that patients responding poorly to anti-VEGFs tended to do so early in the course of treatment. It also demonstrated the effectiveness of a pro re nata (PRN) protocol for improving vision and maintaining these gains over long-term follow-ups. The SHORE study further illustrated this point by demonstrating that there were minimal differences in visual outcomes between patients receiving monthly injections and patients being treated PRN. In this review we analyzed the data from the major randomized clinical trials (RCT) that looked at anti-VEGFs as the primary treatment modality in patients with CRVO (CRUISE and the extension studies HORIZON and RETAIN for ranibizumab as well as GALILEO and COPERNI-CUS for aflibercept). In addition, we looked at SCORE and GENEVA to help determine whether there is a place for steroids as a first line therapy in current treatment practice. We then explored alternative treatment regimens such as laser therapy and switching between anti-VEGF agents and/or steroids for non or partially responding patients. Finally, we propose a simplified modified treatment algorithm for patients with CRVO for better long-term outcomes in all types of responders.

show abstract

Section: Afliberceptmentioning

confidence: 98%

“…17,18 A summary of the major aflibercept trials as well as a comparison with CRUISE, SCORE, and GENEVA is summarized in Table 2. It can be difficult to compare data between different trials, especially if baseline criteria and primary/secondary end points are different.…”

Section: Afliberceptmentioning

confidence: 99%

Central retinal vein occlusion: modifying current treatment protocols

Ashraf

Souka

Singh

2016

Eye

View full text Add to dashboard Cite

show abstract

“…Aflibercept received FDA approval in November 2011 for AMD, September 2012 for RVO, July 2014 for DME, and March 2015 for diabetic retinopathy. Aflibercept has been proven in large, randomized clinical trials for treating AMD in VIEW1 and 2 (Heier et al 2012), CRVO in GALILEO (Korobelnik et al 2014), BRVO in VIBRANT (Campochiaro et al 2015), and DME in DA VINCI (Do et al 2012).…”

Section: Rvomentioning

confidence: 99%

Corticosteroids and Anti-Complement Therapy in Retinal Diseases

Narayanan

Kuppermann

2016

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

“…Laser photocoagulation was the standard therapy for patients with ME secondary to BRVO, but it was not found to have benefit in patients with ME secondary to CRVO [6,7]. More recently, studies have shown benefit of steroid implantation and anti-Vascular Endothelial Growth Factor (anti-VEGF) therapies for the management of patients with ME secondary to RVO [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Untitled

2015

OCR

View full text Add to dashboard Cite

Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion

Cited by 253 publications

References 12 publications

Central retinal vein occlusion: modifying current treatment protocols

Central retinal vein occlusion: modifying current treatment protocols

Corticosteroids and Anti-Complement Therapy in Retinal Diseases

Untitled

Contact Info

Product

Resources

About